• 1
    Rahman A, Isenberg DA: Systemic lupus erythematosus. N Engl J Med 2008; 358:929939.
  • 2
    Madazli R, Bulut B, Erenel H, Gezer A, Guralp O: Systemic lupus erythematosus and pregnancy. J Obstet Gynaecol 2010; 30:1720.
  • 3
    Deng Y, Tsao BP: Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev 2010; 6:683692.
  • 4
    Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J: Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001; 294:15401543.
  • 5
    Wandstrat AE, Carr-Johnson F, Branch V, Gray H, Fairhurst AM, Reimold A, Karp D, Wakeland EK, Olsen NJ: Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus. J Autoimmun 2006; 27:153160.
  • 6
    Li QZ, Karp DR, Quan J, Branch VK, Zhou J, Lian Y, Chong BF, Wakeland EK, Olsen NJ: Risk factors for ANA positivity in healthy persons. Arthritis Res Ther 2011; 13:R38.
  • 7
    Almqvist N, Winkler TH, Martensson IL: Autoantibodies: focus on anti-DNA antibodies. Self Nonself 2011; 2:1118.
  • 8
    Tsokos GC: Systemic lupus erythematosus. N Engl J Med 2011; 365:21102121.
  • 9
    Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH, Alcocer-Varela J, Grangeot-Keros L, Alarcon-Segovia D, Wijdenes J, Galanaud P, Emilie D: Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000; 43:17901800.
  • 10
    Ronnblom L, Alm GV: Systemic lupus erythematosus and the type I interferon system. Arthritis Res Ther 2003; 5:6875.
  • 11
    Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4:330336.
  • 12
    Cederbom L, Hall H, Ivars F: CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 2000; 30:15381543.
  • 13
    Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T: Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med 1985; 161:7287.
  • 14
    Sakaguchi S: Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000; 101:455458.
  • 15
    Hsu WT, Suen JL, Chiang BL: The role of CD4CD25 T cells in autoantibody production in murine lupus. Clin Exp Immunol 2006; 145:513519.
  • 16
    Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F: Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001; 27:6873.
  • 17
    Scalapino KJ, Tang Q, Bluestone JA, Bonyhadi ML, Daikh DI: Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol 2006; 177:14511459.
  • 18
    Gerli R, Nocentini G, Alunno A, Bocci EB, Bianchini R, Bistoni O, Riccardi C: Identification of regulatory T cells in systemic lupus erythematosus. Autoimmun Rev 2009; 8:426430.
  • 19
    Bonelli M, Savitskaya A, von Dalwigk K, Steiner CW, Aletaha D, Smolen JS, Scheinecker C: Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol 2008; 20:861868.
  • 20
    Crispin JC, Martinez A, Alcocer-Varela J: Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2003; 21:273276.
  • 21
    Barath S, Soltesz P, Kiss E, Aleksza M, Zeher M, Szegedi G, Sipka S: The severity of systemic lupus erythematosus negatively correlates with the increasing number of CD4+CD25(high)FoxP3+ regulatory T cells during repeated plasmapheresis treatments of patients. Autoimmunity 2007; 40:521528.
  • 22
    Barath S, Aleksza M, Tarr T, Sipka S, Szegedi G, Kiss E: Measurement of natural (CD4+CD25high) and inducible (CD4+IL-10+) regulatory T cells in patients with systemic lupus erythematosus. Lupus 2007; 16:489496.
  • 23
    Lyssuk EY, Torgashina AV, Soloviev SK, Nassonov EL, Bykovskaia SN: Reduced number and function of CD4+CD25 high FoxP3+ regulatory T cells in patients with systemic lupus erythematosus. Adv Exp Med Biol 2007; 601:113119.
  • 24
    Valencia X, Yarboro C, Illei G, Lipsky PE: Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007; 178:25792588.
  • 25
    Crome SQ, Wang AY, Levings MK: Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease. Clin Exp Immunol 2010; 159:109119.
  • 26
    Onishi RM, Gaffen SL: Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010; 129:311321.
  • 27
    Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW: Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008; 127:385393.
  • 28
    Wong CK, Ho CY, Li EK, Lam CW: Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000; 9:589593.
  • 29
    Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, Fabien N, Cochat P, Pouteil-Noble C, Trolliet P, Durieu I, Tebib J, Kassai B, Ansieau S, Puisieux A, Eliaou JF, Bonnefoy-Berard N: Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009; 10:778785.
  • 30
    Zhao XF, Pan HF, Yuan H, Zhang WH, Li XP, Wang GH, Wu GC, Su H, Pan FM, Li WX, Li LH, Chen GP, Ye DQ: Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol Biol Rep 2010; 37:8185.
  • 31
    Alunno A, Bartoloni E, Bistoni O, Nocentini G, Ronchetti S, Caterbi S, Valentini V, Riccardi C, Gerli R: Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. Clin Dev Immunol 2012; 2012:823085.
  • 32
    Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM: Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198:18751886.
  • 33
    Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235238.
  • 34
    Sharma MD, Hou DY, Liu Y, Koni PA, Metz R, Chandler P, Mellor AL, He Y, Munn DH: Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 2009; 113:61026111.
  • 35
    Becker-Merok A, Eilertsen GO, Nossent JC: Levels of transforming growth factor-beta are low in systemic lupus erythematosus patients with active disease. J Rheumatol 2010; 37:20392045.
  • 36
    Jackson M, Ahmad Y, Bruce IN, Coupes B, Brenchley PE: Activation of transforming growth factor-beta1 and early atherosclerosis in systemic lupus erythematosus. Arthritis Res Ther 2006; 8:R81.
  • 37
    Chen DY, Chen YM, Wen MC, Hsieh TY, Hung WT, Lan JL: The potential role of Th17 cells and Th17-related cytokines in the pathogenesis of lupus nephritis. Lupus 2012; 21:13851396.
  • 38
    Ernerudh J, Berg G, Mjosberg J: Regulatory T helper cells in pregnancy and their roles in systemic versus local immune tolerance. Am J Reprod Immunol 2011; 66(Suppl 1):3143.
  • 39
    Aluvihare VR, Kallikourdis M, Betz AG: Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 2004; 5:266271.
  • 40
    Robertson SA, Guerin LR, Moldenhauer LM, Hayball JD: Activating T regulatory cells for tolerance in early pregnancy – the contribution of seminal fluid. J Reprod Immunol 2009; 83:109116.
  • 41
    Zheng Y, Josefowicz S, Chaudhry A, Peng XP, Forbush K, Rudensky AY: Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 2010; 463:808812.
  • 42
    Samstein RM, Josefowicz SZ, Arvey A, Treuting PM, Rudensky AY: Extrathymic generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict. Cell 2012; 150:2938.
  • 43
    Somerset DA, Zheng Y, Kilby MD, Sansom DM, Drayson MT: Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology 2004; 112:3843.
  • 44
    Chirico D, Bruce I, Baker P, Tower C: Predictors of pregnancy complications in women with systemic lupus erythematosus. BJOG 2009; 116:1407.
  • 45
    Sasaki Y, Sakai M, Miyazaki S, Higuma S, Shiozaki A, Saito S: Decidual and peripheral blood CD4+CD25+ regulatory T cells in early pregnancy subjects and spontaneous abortion cases. Mol Hum Reprod 2004; 10:347353.
  • 46
    Xiong H, Zhou C, Qi G: Proportional changes of CD4+CD25+Foxp3+ regulatory T cells in maternal peripheral blood during pregnancy and labor at term and preterm. Clin Invest Med 2010; 33:E422.
  • 47
    Mjosberg J, Svensson J, Johansson E, Hellstrom L, Casas R, Jenmalm MC, Boij R, Matthiesen L, Jonsson JI, Berg G, Ernerudh J: Systemic reduction of functionally suppressive CD4dimCD25highFoxp3+ Tregs in human second trimester pregnancy is induced by progesterone and 17beta-estradiol. J Immunol 2009; 183:759769.
  • 48
    Tilburgs T, Roelen DL, van derMast BJ, van Schip JJ, Kleijburg C, de Groot-Swings GM, Kanhai HH, Claas FH, Scherjon SA: Differential distribution of CD4(+)CD25(bright) and CD8(+)CD28(-) T-cells in decidua and maternal blood during human pregnancy. Placenta 2006; 27(Suppl A):S47S53.
  • 49
    Arruvito L, Sotelo AI, Billordo A, Fainboim L: A physiological role for inducible FOXP3(+) Treg cells. Lessons from women with reproductive failure. Clin Immunol 2010; 136:432441.
  • 50
    Liu YS, Wu L, Tong XH, Wu LM, He GP, Zhou GX, Luo LH, Luan HB: Study on the relationship between Th17 cells and unexplained recurrent spontaneous abortion. Am J Reprod Immunol 2010; 65:503511.
  • 51
    Wang WJ, Hao CF, Qu QL, Wang X, Qiu LH, Lin QD: The deregulation of regulatory T cells on interleukin-17-producing T helper cells in patients with unexplained early recurrent miscarriage. Hum Reprod 2010; 25:25912596.
  • 52
    Wang WJ, Hao CF, Yi L, Yin GJ, Bao SH, Qiu LH, Lin QD: Increased prevalence of T helper 17 (Th17) cells in peripheral blood and decidua in unexplained recurrent spontaneous abortion patients. J Reprod Immunol 2010; 84:164170.
  • 53
    Yang H, Qiu L, Chen G, Ye Z, Lu C, Lin Q: Proportional change of CD4+CD25+ regulatory T cells in decidua and peripheral blood in unexplained recurrent spontaneous abortion patients. Fertil Steril 2008; 89:656661.
  • 54
    Scarpellini F, Sbracia M: Use of granulocyte colony-stimulating factor for the treatment of unexplained recurrent miscarriage: a randomised controlled trial. Hum Reprod 2009; 24:27032708.
  • 55
    Santner-Nanan B, Peek MJ, Khanam R, Richarts L, Zhu E, Fazekas de St Groth B, Nanan R: Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia. J Immunol 2009; 183:70237030.
  • 56
    Tower C, Crocker I, Chirico D, Baker P, Bruce I: SLE and pregnancy: the potential role for regulatory T cells. Nat Rev 2011; 7:124128.
  • 57
    Varghese S, Crocker I, Bruce IN, Tower C: Systemic lupus erythematosus, regulatory T cells and pregnancy. Expert Rev Clin Immunol 2011; 7:635648.
  • 58
    Nelson-Piercy C: Handbook of Obstetric Medicine, 3rd edn. Abingdon, UK, Informa Healthcare, 2006.
  • 59
    Le Thi Huong D, Wechsler B, Piette JC, Bletry O, Godeau P: Pregnancy and its outcome in systemic lupus erythematosus. QJM 1994; 87:721729.
  • 60
    Carvalheiras G, Vita P, Marta S, Trovao R, Farinha F, Braga J, Rocha G, Almeida I, Marinho A, Mendonca T, Barbosa P, Correia J, Vasconcelos C: Pregnancy and systemic lupus erythematosus: review of clinical features and outcome of 51 pregnancies at a single institution. Clin Rev Allergy Immunol 2010; 38:302306.
  • 61
    Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD: A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010; 5:20602068.
  • 62
    Ritchie J, Smyth A, Tower C, Helbert M, Venning M, Garovic V: Maternal deaths in women with lupus nephritis: a review of published evidence. Lupus 2012; 21:534541.
  • 63
    Hughes GR: The anticardiolipin syndrome. Clin Exp Rheumatol 1985; 3:285286.
  • 64
    Ruiz-Irastorza G, Khamashta MA: Antiphospholipid syndrome in pregnancy. Rheum Dis Clin North Am 2007; 33:287297, vi
  • 65
    Petri M, Qazi U: Management of antiphospholipid syndrome in pregnancy. Rheum Dis Clin North Am 2006; 32:591607.
  • 66
    Galli M, Luciani D, Bertolini G, Barbui T: Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101:18271832.
  • 67
    Lockshin MD, Kim M, Laskin CA, Guerra M, Branch DW, Merrill J, Petri M, Porter TF, Sammaritano L, Stephenson MD, Buyon J, Salmon JE: Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012; 64:23112318.